Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer

By afschroeder • August 22, 2025

Konecny GE, Davidson TM, Lebreton CL, Marsh LA, Chetram DK, Atkinson HJ, Larson MC, Oberg AL, Abdelaal N, Silverstein J, Jatoi A, Washburn A, Burton J, Dowdy S, Zhang L, Hallberg D, Velculescu VE, Slamon DJ, Wahner-Hendrickson AE. Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2025 Jul 28;35(10):102028. doi: 10.1016/j.ijgc.2025.102028. Epub ahead of print. PMID: 40839974.

Tags: CDK4/6 inhibitor, Cyclin-Dependent Kinases, Fellow, Hematology/Oncology, ovarian cancer, Palbociclib, Publications, targeted therapy

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan[...]

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome[...]

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams[...]